89. Jahrestagung der Deutschen Gesellschaft für Kardiologie

Donnerstag, 13. April 2023 (Posterbereich 15) 09:30-11:00

Postervorträge

Kardiale Amyloidose

Diskussionsleitung: D. Lavall (Leipzig), C. Morbach (Würzburg)

(P518) Common and Distinct Features of Transthyretin Amyloid Cardiomyopathy and Heart Failure with Preserved Ejection Fraction – Implications for Screening – The AMY Score
    G. Gioia, L. Schrutka, J. Jozwiak-Nozdrzykowska, H. Gunold, K. Klingel, H. Thiele, D. Bonderman, P. Lurz, K.-P. Rommel (Leipzig, Tübingen; Wien, AT)
(P519) Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis
    M. Papathanasiou, L. Kessler, A. M. Jakstaite, D. Kersting, E. Alyaydin, P. Lüdike, A. Carpinteiro, K. Herrmann, T. Rassaf, C. Rischpler (Essen)
(P520) Tafamidis in cardiac wt-ATTR-amyloidosis – one year follow-up data
    I. Yan, J. C. M. Franke, R. Frauen, N. Diermann, C. Chevalier, P. Kirchhof, K. Müllerleile, M. Patten-Hamel (Hamburg)
(P521) Predictors of functional status in transthyretin amyloid cardiomyopathy
    M. Paulus, S. Hegner, C. Meindl, M. Hamerle, L. S. Maier, B. Unsöld (Regensburg)
(P522) Prevalence and predictors of ventricular arrhythmias in amyloid transthyretin cardiomyopathy
    K. Knoll, P. Fuchs, I. Weidmann, S. Groß, F. Altunkas, C. Lennerz, C. Kolb, T. Keßler, H. Schunkert, W. Reinhard, T. Trenkwalder (München, Greifswald)
(P523) Screening for occult transthyretin amyloidosis in patients with degenerative aortic stenosis and amyloid red-flags
    A. M. Jakstaite, P. Lüdike, R. A. Janosi, L. Michel, F. Al-Rashid, E. Alyaydin, A. Carpinteiro, C. Rischpler, K. Herrmann, T. Rassaf, M. Papathanasiou (Essen)
(P524) Increasing prevalence of advanced cardiac amyloidosis among cardiac and non-cardiac patients undergoing echocardiography in a university heart center – A cohort study of the last decade
    R. B. Albrecht, A. Hamadanchi, J. G. Westphal, M. Franz, P. Aftanski, T. Kräplin, C. Schulze, S. Otto (Jena)
(P525) mRNA vaccines for COVID-19 are safe and effective in patients with cardiac amyloidosis
    G. Barzen, F. Rieber, K. Hahn, K. Stangl, S. Spethmann (Berlin)